Highlights Quantum Genomics OTC Markets

Equities

QNNTF

FR0011648971

Market Closed - OTC Markets Other stock markets 16:33:55 22/04/2024 BST			5-day change	1st Jan Change
0.1 ^USD	-0.99%		-.--%	-0.99%

03-13	Quantum Genomics Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Quantum Genomics Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Quantum Genomics Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Quantum Genomics Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	24/10/23	CI
Quantum Genomics Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	26/05/23	CI
Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, Fresh and Is Redirecting to New Developments	28/10/22	CI
Quantum Genomics Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2022	05/10/22	CI
Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH	09/05/22	CI
Quantum Genomics Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2021	28/04/22	CI
Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606	31/03/22	CI
Quantum Genomics Secures New Patents For Potential Heart Drug QGC606	29/03/22	MT
Quantum Genomics Announces Granting of New Patents Protecting QGC606	28/03/22	CI
Quantum Genomics Société Anonyme Signs an Exclusive License and Production Agreement with Julphar	06/12/21	CI
Quantum Genomics Signs an Exclusive License Agreement with Teva Israel Ltd	25/11/21	CI
Quantum Genomics Société Anonyme and its Partners Reach a New Stage of Development in Asia	07/10/21	CI
Quantum Genomics Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2021	06/10/21	CI
Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat	27/08/21	CI
Global markets live: Microsoft, Deliveroo, Didi, Biogen, Tesla...	08/07/21
Quantum Genomics Enrolls First Patient in Its Pivotal Phase III REFRESH Trial of Firibastat in Difficult-to-Treat and Resistant Hypertension with Once-a-Day Formulation of Firibastat	08/07/21	CI
Global markets live: WM Morrison, IBM, Didi...	05/07/21
Quantum Genomics Will Present Top-Line Results from its Quorum Study of Firibastat in Heart Failure Post Myocardial Infarction	21/04/21	CI
Quantum Genomics Announces the End of its Collaboration with Qilu for the Development and Commercialization of Firibastat in China	20/04/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Quantum Genomics OTC Markets

Equities

QNNTF

FR0011648971

Highlights

Filters